Kyorin Pharma To Shut Down US Subsidiary ActivX
End Of Line For 2004 Acquisition
Executive Summary
Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.
You may also be interested in...
Eisai To Shut Down H3 In Global R&D Restructuring
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Kyorin's DPP-4 inhibitor shows Phase II promise
The first Phase II data for Kyorin Pharmaceutical's DPP-4 inhibitor KRP-104 show statistically significant reductions in haemoglobin A1c (HbA